Literature DB >> 27867902

Hypocalcemia and Fahr syndrome in a patient with Graves' disease: Difficult etiological diagnosis.

Ibtissem Oueslati1, Karima Khiari1, Najla Bchir1, Néjib Ben Abdallah1.   

Abstract

Entities:  

Year:  2016        PMID: 27867902      PMCID: PMC5105583          DOI: 10.4103/2230-8210.192907

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, Graves’ disease is an autoimmune disorder typically characterized by the presence of circulating autoantibodies that tie to and stimulate the thyroid hormone receptor, resulting in hyperthyroidism, and goiter.[1] Hyperthyroidism is known to cause a relatively mild hypercalcemia secondary to an increase in bone turnover and mobilization of calcium from bone into the circulation.[2] Fahr syndrome is a rare inherited or sporadic neurological disorder characterized by the presence of bilateral intracranial calcifications with predilection for the basal ganglia and dentate nuclei.[3] It is commonly associated with endocrine disorders, particularly parathyroid and Vitamin D disturbances. A 29-year-old male was referred to our department with a malignant Graves’ ophthalmopathy. One year ago, he was diagnosed with Graves’ disease and treated with benzylthiouracil. While thyrotoxicosis symptoms showed improvement, the proptosis deteriorated following the initiation of antithyroid drug. On examination, he had a body weight of 48 kg, a body mass index of 17 kg/m2, a blood pressure of 120/80 mmHg, and a regular pulse of 80 beats/min and diffusely enlarged thyroid gland. He had a bilateral and asymmetric proptosis with conjunctive edema, hyperemia, and vertical diplopia. No typical findings of Albright's hereditary osteodystrophy were observed. Moreover, Trousseau and Chvostek signs were negative. The rest of clinical examination and the electrocardiograph were normal. Laboratory investigations revealed normal thyroid tests, normal renal function, hypocalcemia of 1.77 mmol/L (normal range: 2.1–2.55), hyperphosphatemia of 1.8 mmol/L (normal range: 0.74–1.52), calciuria of 1.2 mmol/24 h, serum magnesium of 0.86 mmol/L (normal range: 0.66–1.07), serum alkaline phosphatase of 94 U/L (normal range: 40–150 U/L), serum albumin of 50.3 g/L (normal range: 38–56), a low 25 OH Vitamin D level (9.3 µg/L, normal range: 30–80 µg/L), and elevated parathormone level of 203.3 pg/ml (normal range: 15–68.3). Urinary cyclic adenosine monophosphate level and Gsα subunit assay were not available. Ultrasound of the neck showed enlarged thyroid gland with an intense vascularity; no nodules were identified. Orbital computed tomography showed Grade III left proptosis [Figure 1].
Figure 1

Orbital computed tomography showed Grade III left proptosis

Orbital computed tomography showed Grade III left proptosis Computed tomography scan of the brain revealed Fahr syndrome with a bilateral and symmetric striatopallidal calcifications [Figure 2]. The bone mineral density showed osteopenia.
Figure 2

Computed tomography-scan of the brain revealed Fahr syndrome with a bilateral and symmetric striatopallidal calcifications

Computed tomography-scan of the brain revealed Fahr syndrome with a bilateral and symmetric striatopallidal calcifications The patient was prescribed Vitamin D supplementation, calcium gluconate, and corticosteroids. After 3 months, serum calcium level was found to be 2.07 mmol/L, and phosphatemia was found to be 1.5 mmol/L. The serum parathyroid hormone (PTH) was persistently high (163.8 pg/ml). Hypocalcemic disorders with a normal to elevated serum phosphate level can be subdivided into hypoparathyroidism and pseudohypoparathyroidism (PHP) in the absence of chronic renal failure. In our patient, the diagnosis of hypoparathyroidism was ruled out according to the high PTH level. In this case, low 25 OH Vitamin D level was consistent with the diagnosis of secondary hyperparathyroidism due to Vitamin D deficiency. Typically, Vitamin D deficiency is associated with normal or decreased serum phosphorus levels. However, in some patients, marked hypocalcemia is accompanied by normo- or hyperphosphatemia.[4] PHP has been reported as a cause of Fahr syndrome. It constitutes a very rare group of heterogeneous disorders characterized by hypocalcemia, hyperphosphatemia, normal or increased PTH secretion, and target tissue resistance to the actions of PTH.[5] Most reported cases of PHP Type II are preceded by or simultaneously present with autoimmune disorders, such as Sjogren's syndrome, Hashimoto's thyroiditis, or Graves’ disease.[5] According to the biochemical similarities between Vitamin D deficiency and PHP, differential diagnosis based on routine biochemistry can be difficult.[6]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  6 in total

1.  Vitamin D deficiency in two young adults with biochemical findings resembling pseudohypoparathyroidism type I and type II.

Authors:  Toshiro Seki; Michiko Yamamoto; Hironari Kimura; Mika Tsuiki; Masami Ono; Nobuhiro Miki; Kazue Takano; Kanji Sato
Journal:  Endocr J       Date:  2010-05-25       Impact factor: 2.349

2.  The Fahr syndrome and the chronic lymphocytic thyroiditis.

Authors:  Anca Sava; Gabriela Dumitrescu; Danisia Haba; Diana Hodorog; Claudia Mihailov; Elena Şapte
Journal:  Rom J Morphol Embryol       Date:  2013       Impact factor: 1.033

Review 3.  Diagnosis and classification of Graves' disease.

Authors:  Francesca Menconi; Claudio Marcocci; Michele Marinò
Journal:  Autoimmun Rev       Date:  2014-01-12       Impact factor: 9.754

4.  Vitamin D deficiency masquerading as pseudohypoparathyroidism type 2.

Authors:  M Shriraam; A Bhansali; P Velayutham
Journal:  J Assoc Physicians India       Date:  2003-06

5.  Pseudohypoparathyroidism type II in a woman with a history of thyroid surgery.

Authors:  Takaaki Murakami; Takuo Nambu; Yuki Morimoto; Yuki Matsuda; Koji Matsuo; Shin Yonemitsu; Seiji Muro; Shogo Oki
Journal:  Intern Med       Date:  2012-03-01       Impact factor: 1.271

Review 6.  Bone disease in thyrotoxicosis.

Authors:  P Amaresh Reddy; C V Harinarayan; Alok Sachan; V Suresh; G Rajagopal
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.